SPY на уровне вчерашнего закрытия

Ближайший уровень поддержки по SPY – 200.30 уровень сопротивления – 200.60
 

AMGN смотрим на покупку выше 137
 
CMCM смотрим за ним
 
Gapping up/down: EXPR +14% and ARUN +8% after earnings, MNKD +4% after initiation with Buy at Jefferies; SWHC -11% and TIVO -2% after earnings, LEJU -4% after dg at GS


Gapping up
In reaction to strong earnings/guidance: TUBE +32.5%, EXPR +13.9%, ARUN +8%, DCI +5.7%, NMBL +2.9%, TIF +2.7%, HEI +2.3%, REX +1.8%, BWS +1.4%
M&A news: OIBR +1.8% (Engagement of Banco BTG Pactual to act as agent to review alternatives to the acquisition of the shares of TIM)
Other news: ISNS +25.9% (seeing continued strength — another recent security play, ie DGLY, TASR), AEGR +8.2% (announces resolution of warning letter for JUXTAPID (lomitapide) capsules), PKT +6.9% (receives $5 mln in initial orders from Tier 1 European MSO), ALTV +5.4% (following late move higher on Juniper Investment Company amended 13D filing with proposal for an all-cash acquisition of $8/share), RSH +4.7% (continued strength following yesterday's rumors on potential financing), RYAAY +3.6% (launched Ryanair Business Plus), PT +3.5% (still checking), CLUB +3.4% (Farallon Capital files amended 13D; indicates company should be prepared to evaluate potential acquirers' interest and engage financial advisor ), YOKU +3.3% (announces up to $300 mln share repurchase program), HZNP +2.5% (announces the USPTO issuance of an additional notice of allowance with claims covering RAYOS delayed-release tablets), ARO +2.1% (in sympathy with EXPR), MBLY +1.9% (cont strength), GALE +1.7% (still checking), KLIC +1.7% (authorized the repurchase of up to $100 mln of co's common shares), TRNS +1.4% (co increased secured revolving credit facility to $30 mln, up from $20 mln; $15 mln now available for acquisitions, up from previous $10 mln), ALLT +1.2% (in sympathy with PKT (closest peer)), DGLY +1.2% (cont momentum), BRCM +1.2% (Netatmo has selected the Broadcom Wireless Internet Connectivity for Embedded Devices Wi-Fi technology), LGND +1% (partner GSK receives FDA approval for Promacta/Revolade for use in patients with severe aplastic anemia), GSK +1% (receives FDA approval for Promacta/Revolade for use in patients with severe aplastic anemia), STJ +0.9% (resolves FDA Warning Letter for Plano Facility)

Analyst comments: ACLS +9.4% (initiated with a Buy at Stifel), MNKD +3.7% (initiated with a Buy at Jefferies), RCII +2.9% (upgraded to Buy from Hold at Canaccord Genuity), HTH +2.3% (upgraded to Outperform from Mkt Perform at Keefe Bruyette), TTI +1.8% (upgraded to Outperform at Cowen), LVLT +1.3% (upgraded to Outperform from Neutral at Macquarie)
 
Gapping down
In reaction to disappointing earnings/guidance: SWHC -11.1%, DAEG -10.9%, YGE -4.8%, CHS -4.7%, SDRL -4.2%, TIVO -2.2%, (announces new $350 mln share repurchase plan), SLH -1.6%, BMRN -1.3%, (adjusted guidance to reflect one-time sale item), DY -1.2%, BF.B -0.8%
M&A news: COV -1.5% (investor has filed lawsuit to block Medtronic (MDT) deal, according to reports)
Other news: TLM -4.1% (seeing reports that co's discussions with Repsol (REPYY) regarding a potential deal for the sale of assets have stalled), RGR -3.5% (following SWHC results), AR -0.8% (co raised its production guidance and 2014 capital budget to $3.7 bln), OWW -0.5% (OWW issues statement regarding American Airlines action; Orbitz for Business is not impacted)
Analyst comments: LEJU -4.4% (downgraded to Neutral from Buy at Goldman), RGR -3.5% (downgraded to Fair Value from Buy at CRT Capital, also in sympathy with SWHC), EJ -2.7% (downgraded to Neutral from Buy at Goldman), FB -0.5% (downgraded to Neutral from Buy at Janney)
Оригинал статьи: gtstocks.com/analytics-27-08-2014.html